

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED
(Company Registration No. 91120000103100784F)
(Incorporated in People's Republic of China)

RESOLUTIONS PASSED AT THE 3RD BOARD MEETING FOR FY2022

The board of directors (the “Board”) and every individual director of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “Company”, together with its subsidiaries, the “Group”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Company had on 28 April 2022 duly convened its 3rd Board meeting for the financial year ending 31 December 2022 (“FY2022”) by means of live meeting and telephone conference. The said meeting was convened in compliance with the applicable Companies Law, Securities Law and the Articles of Association of the Company, and the following resolutions were discussed and passed by the 9 directors out of the full board of 9 directors:

1. That, the full text and summary of the first quarter financial statement for FY2022 prepared in accordance with the accounting standards of the People's Republic of China and the International Financial Reporting Standards, be approved.

The Board and management of the Company confirmed that as far as they are aware, there are no material facts the omission of which would make the aforesaid financial statement misleading.

2. That, the proposed transfer of the entire equity interest held by the Company in Tianjin Da Ren Tang (Bozhou) Chinese Medicine Co., Ltd (天津达仁堂(亳州)中药饮片有限公司) (“**Da Ren Tang (Bozhou)**”) to Tianjin Chinese Medicinal Slices Co., Ltd. (天津市中药饮片厂有限公司) (“**Chinese Medicinal Slices Co.**”), be approved.

To optimise the organisational structure of the Group, improve the management efficiency, accelerate resource integration and realise industrial integration and coordination, the Company proposes to transfer the entire equity interest held by it in its wholly-owned subsidiary, Da Ren Tang (Bozhou) to its another wholly-owned subsidiary, Chinese Medicinal Slices Co. (the “**Proposed Transfer**”). Upon the completion of the Proposed Transfer, Da Ren Tang (Bozhou) will become a wholly-owned subsidiary of Chinese Medicinal Slices Co..

3. That, upon nomination and deliberation at a meeting of the Office of General Manager of the Company and review by the Nomination Committee of the Company, the proposed appointment of Mr. Zhang Yu (张宇) as Chief Production Officer (CPO) of the Company, be approved.

Mr. Zhang Yu (张宇), born in September 1973, holds a Master of Engineering Degree and is a senior engineer. From July 1995 to May 2019, Mr. Zhang worked for the Company's Le Ren Tang Pharmaceutical Factory (天津中新药业乐仁堂制药厂), where he successively served as Regional Manager of the Sales Branch, Head of the Science and Technology Quality Department, Production

Director, Assistant to the Factory Director and Chief Engineer. From May 2019 to March 2022, Mr. Zhang served as Deputy Director of the Operation Management Department and Deputy Director of the Production Operation Department of Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司).

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
29 April 2022